Loading...
01/11 07:56
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong revenue growth, improved gross margins, and a significant reduction in net loss, which are positive indicators. The Q&A section reveals confidence in achieving adjusted EBITDA positivity and a positive outlook on capital needs. However, there are some concerns regarding competition and unclear responses on specific financial metrics. Overall, the positive aspects outweigh the negatives, leading to a positive sentiment rating.
Total Revenue $21.8 million, a 20% increase over the prior year. The increase is attributed to growth in lung diagnostic testing revenue and development services revenue.
Lung Diagnostic Testing Revenue $19.8 million from approximately 15,700 tests, compared to $17.2 million from approximately 13,900 tests in the third quarter of 2024. This represents 13% growth in test volumes and 16% growth in revenue. The growth is due to increased test adoption and higher average revenue per test.
Development Services Revenue $1.9 million, representing 97% year-over-year growth. The growth is attributed to strong interest in partnership service offerings and an increase in contracts under development services.
Gross Margin Percentage 81%, up 400 basis points from 77% in the third quarter of 2024. The improvement is due to operational efficiencies and process improvements.
Operating Expense (Excluding Direct Costs and Expenses) $24.7 million, a 10% increase over the third quarter of 2024 but a 4% decrease versus the second quarter of 2025. The increase year-over-year is due to scaling operations, while the quarter-over-quarter decrease reflects cost-conscious measures.
SG&A Expense $21.7 million, an 8% increase year-over-year but a 3% decrease versus the second quarter of 2025. The increase is due to scaling the sales team, while the decrease reflects operational efficiencies.
R&D Expense $3.0 million, a $500,000 increase year-over-year but a $300,000 decrease from the second quarter of 2025. The increase is due to investments in clinical studies and pipeline advancement.
Net Loss $8.7 million, an improvement of 15% year-over-year and 24% over the second quarter of 2025. The improvement is due to revenue growth and cost management.
Adjusted EBITDA Loss of $4.6 million, an improvement of 18% year-over-year and 36% over the second quarter of 2025. The improvement is attributed to revenue growth and operational efficiencies.
Unrestricted Cash and Cash Equivalents $16.6 million, impacted by timing of collections, a $5.2 million increase in accounts receivable, and net cash inflows of $4.8 million from the ATM facility.
Nodify Lung Testing: Expanded into primary care, increasing test orders from primary care by 75% year-over-year. Total tests ordered grew to 15,700, up 13% year-over-year. Average revenue per test improved by 7%.
Development Services: Revenue grew 97% year-over-year to $1.9 million. Contracted revenue reached $12.9 million, a 16% increase year-over-year.
MRD Test: Presented multiple updates on the combination proteomic and genomic MRD test at various conferences.
Primary Care Expansion: Expanded access to 50% of patients with pulmonary nodules managed in primary care. Increased primary care test orders from 4% to 11%.
Partnerships: Expanded product development partnership with Bio-Rad Laboratories for high-complexity in vitro diagnostic assays.
Revenue Growth: Total revenue increased by 20% year-over-year to $21.8 million. Lung diagnostic testing revenue grew by 16%.
Gross Margins: Improved gross margins by 400 basis points to 81%.
Adjusted EBITDA: Improved by 18% year-over-year, with a loss of $4.6 million.
Sales Team Expansion: Increased sales reps to an average of 85 in Q3, with plans to grow to 93-97 in Q4.
Digital Ordering: Increased digital test ordering by 43% year-over-year, enhancing customer retention.
Medicare Advantage plans payment issues: Several Medicare Advantage plans had instituted administrative barriers to paying claims for Medicare-covered tests. Although one of the largest plans restarted paying for current claims, older claims remain unresolved, impacting revenue collection.
Supply cost pressures and macroeconomic uncertainty: Despite achieving strong gross margins, the company faces continued supply cost pressures and macroeconomic uncertainties, which could affect profitability and operational stability.
Patient compliance challenges: The company faces challenges in ensuring patient compliance for blood draws, particularly when patients need to schedule blood draws at another time or location, potentially impacting test completion rates.
Scaling sales team: The company is expanding its sales team, which increases operational costs. While this is aimed at driving growth, it poses a risk if the additional sales reps do not achieve expected productivity levels.
Regulatory and reimbursement hurdles: The company is involved in clinical validation and regulatory submissions for new diagnostic assays, which could face delays or challenges, impacting the timeline for new product launches.
Economic uncertainties affecting collections: Timing of collections has impacted cash flow, as seen in the $5.2 million increase in accounts receivable, which could pose liquidity risks if not managed effectively.
Revenue Guidance for 2025: The company has increased its revenue guidance range for 2025 to $84 million to $86 million, based on strong third-quarter performance and early fourth-quarter momentum.
Adjusted EBITDA: The company expects to achieve adjusted EBITDA positivity in the fourth quarter of 2025, supported by strong gross margins and increased sales team productivity.
Gross Margins: Gross margins are expected to remain near 80% for the remainder of 2025, despite supply cost pressures and macroeconomic uncertainties.
Sales Team Expansion: The company plans to have an average of 93 to 97 sales representatives in the field in the fourth quarter of 2025 and anticipates adding approximately 6 representatives per quarter in 2026 to drive patient access to diagnostic testing.
Development Services Revenue: The company reported $1.9 million in development services revenue for Q3 2025, a 97% year-over-year growth, and exited the quarter with $12.9 million under contract, representing a 16% increase over the prior year.
Pipeline Development: The company is advancing its product development pipeline, including a combination proteomic and genomic MRD test, expanded indications for VeriStrat, and digital diagnostics. It has also expanded its partnership with Bio-Rad Laboratories for high-complexity in vitro diagnostic assays.
The selected topic was not discussed during the call.
The earnings call highlights strong revenue growth, improved gross margins, and a significant reduction in net loss, which are positive indicators. The Q&A section reveals confidence in achieving adjusted EBITDA positivity and a positive outlook on capital needs. However, there are some concerns regarding competition and unclear responses on specific financial metrics. Overall, the positive aspects outweigh the negatives, leading to a positive sentiment rating.
The earnings call reflects a positive sentiment with strong revenue growth, a strategic focus on primary care, and digital integration. The Q&A section indicates confidence in revenue-driven EBITDA positivity by Q4, with no major cost-cutting. Although there is an increase in net loss and adjusted EBITDA loss, the overall tone is optimistic, supported by a solid growth strategy and expanding market opportunities. The strategic initiatives and expected revenue acceleration, particularly in Q4, suggest a positive stock price movement in the short term.
The earnings call presents a mixed picture: strong revenue growth and improved margins are positive, but hiring delays and macroeconomic uncertainties pose risks. The Q&A session reveals confidence in the hiring strategy but lacks clarity on revenue impact and efficiency timelines. Despite positive financials, the absence of a share repurchase program and potential hiring delays temper enthusiasm. The company's strategic shift and guidance for profitability in 2025 are encouraging but do not outweigh the uncertainties, resulting in a neutral sentiment for short-term stock price movement.
The earnings call reveals a mixed sentiment. Financial performance shows growth in revenue and improved margins, but there's a net loss and reduced cash reserves. The Q&A section highlights concerns about sales force restructuring and unclear responses from management. Adjusted EBITDA positivity in Q4 2025 and a revised revenue guidance suggest cautious optimism. The lack of clarity and slower hiring may temper market reaction, resulting in a neutral stock price movement prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
